Toby C Rodman

US Patent:

6391635, May 21, 2002

Filed:

May 23, 2000

Appl. No.:

09/577185

Inventors:

Toby C. Rodman - New York NY

Assignee:

Institute for Human Genetics and Biochemistry - Geneva

International Classification:

C12N 134

US Classification:

435346, 435325, 435326, 435328, 435329, 435337, 4353391, 5303875, 5303881, 53038815, 53038825, 53038835

Abstract:

Disclosed herein are method for producing hydridoma cell lines producing monoclonal human natural IgM antibodies and hybridoma cells produced by the methods. The antibodies are the monoclonal equivalents of circulating human natural antibodies.

US Patent:

6610833, Aug 26, 2003

Filed:

Dec 28, 1999

Appl. No.:

09/462118

Inventors:

Toby C. Rodman - New York NY

Assignee:

The Institute for Human Genetics and Biochemistry - Geneva

International Classification:

C07K 1600

US Classification:

53038835, 5303881, 53038815, 4241411, 4241421, 4241481

Abstract:

Disclosed herein are hydridoma cell lines producing monoclonal human natural IgM antibodies and methods of use thereof. The antibodies are the monoclonal equivalents of circulating human natural antibodies. Also disclosed herein are pharmaceutical formulations and methods for treating HIV-1 infected individuals using the monoclonal human natural antibodies.

US Patent:

7122638, Oct 17, 2006

Filed:

Sep 20, 2002

Appl. No.:

10/247946

Inventors:

Toby C. Rodman - New York NY, US

Assignee:

The Institute for Human Genetics and Biochemistry - Geneva

International Classification:

C12P 21/08

US Classification:

5303881, 53038835, 530809

Abstract:

Disclosed herein are hydridoma cell lines producing monoclonal human natural IgM antibodies and methods of use thereof. The antibodies are the monoclonal equivalents of circulating human natural antibodies. Also disclosed herein are pharmaceutical formulations and methods for treating HIV-1 infected individuals using the monoclonal human natural antibodies.

US Patent:

7189826, Mar 13, 2007

Filed:

Sep 20, 2002

Appl. No.:

10/251526

Inventors:

Toby C. Rodman - New York NY, US

Assignee:

Institute for Human Genetics and Biochemistry - Geneva

International Classification:

C07K 16/00

US Classification:

53038835, 4353391

Abstract:

Disclosed herein are hydridoma cell lines producing monoclonal human natural IgM antibodies and methods of use thereof. The antibodies are the monoclonal equivalents of circulating human natural antibodies. Also disclosed herein are pharmaceutical formulations and methods for treating HIV-1 infected individuals using the monoclonal human natural antibodies.

US Patent:

56060262, Feb 25, 1997

Filed:

Apr 26, 1993

Appl. No.:

8/053079

Inventors:

Toby C. Rodman - New York NY

Assignee:

The Institute for Human Genetics and Biochemistry - Geneva

International Classification:

C07K 1600
C07K 1608
C07K 1644

US Classification:

5303879

Abstract:

An isolated human natural IgM antibody immunoreactive with an epitope present on HIV-1 Tat protein is provided. Additionally, a method for the prognosis or diagnosis of AIDS in an individual infected with HIV including the steps of: obtaining a body fluid from the individual, detecting or measuring natural human IgM antibodies in the body fluid of the individual and determining a. DELTA. 20-. DELTA. 2 value, and comparing the. DELTA. 20-. DELTA. 2 value obtained from the individual with a. DELTA. 20-. DELTA. 2 value obtained from clinically normal, non-HIV infected humans, wherein the individual has AIDS or will progress to AIDS within about two years if the individual's. DELTA. 20-. DELTA. 2 value is significantly decreased relative to the. DELTA. 20-. DELTA. 2 value obtained from the clinically normal humans, is provided.

US Patent:

58720120, Feb 16, 1999

Filed:

Jul 5, 1994

Appl. No.:

8/271210

Inventors:

Toby C. Rodman - New York NY

Assignee:

The Institute for Human Genetics and Biochemistry - Geneva

International Classification:

G01N 3353

US Classification:

436518

Abstract:

The present invention is directed to protamine-reactive, IgM antibodies, and their uses in prognosis, diagnosis, and therapy. In a specific embodiment, the invention relates to low affinity binding, protamine-reactive serum IgM antibodies. In particular, such antibodies can recognize a sequence comprising four arginyl residues, including a triplet, within a six amino acid residue sequence. Such antibodies may be natural antibodies (i. e. , not induced). A low affinity subset of serum protamine-reactive IgM antibodies may be assayed for prognosis or diagnosis of AIDS. Such antibodies are detectable in sera of normal subjects and HIV-infected individuals who subsequently exhibit a significant period of latency, but are absent or deficient in sera of individuals diagnosed with AIDS and sera of HIV infected individuals, who though asymptomatic at the time of the sampling, proceed to AIDS within a relatively short time. The invention provides methods and diagnostic kits for the detection and/or measurement of the low affinity subset of protamine-reactive serum IgM antibodies, for the prognosis and diagnosis of AIDS and other immune system abnormalities.